Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Stock Information for Anixa Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Anixa Biosciences Inc.

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.